Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on Isotopically Enriched Forms of ALZ-801/Valiltramiprosate
The decision was affirmed without discussion by the Federal Circuit Court (Case No.
- The decision was affirmed without discussion by the Federal Circuit Court (Case No.
- In 2020, Alzheon petitioned the Patent Trial and Appeal Board (PTAB) of the U.S. Patent Office (USPTO) to institute an Inter-Parties Review (IPR) of Risen’s U.S. Patent No.
- Risen appealed the PTAB’s decision to the United States Court of Appeals for the Federal Circuit.
- “Alzheon is pleased that the U.S. Federal Circuit affirmed the Patent Trial and Appeal Board’s decision to invalidate all claims of Risen’s patent.